|
Match
|
Document |
Document Title |
|
|
US20090298873 |
METHODS OF REDUCING MICROBIAL RESISTANCE TO DRUGS
The instant methods and compositions represent an advance in controlling drug resistance in microbes. AcrAB-like efflux pumps have been found to control resistance to drugs, even in highly...
|
|
|
US20090298872 |
COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROIDAL RECEPTORS AND CALCIUM CHANNEL ACTIVITIES
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorder associated with the activation...
|
|
|
US20090298868 |
QUINOLINE COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF
A method of identification of quinoline compounds (formula I) that modify melanin synthesis (melanogenesis), and the use of such compounds and compositions thereof to control (e.g., inhibit)...
|
|
|
US20090298827 |
NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS
The compounds represented in general formula (1) and a salt thereof are useful for glucocorticoid receptor modulator.
The R 1 represents a hydrogen atom or a lower alkyl group; R 2 represents...
|
|
|
US20090298826 |
NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS
The compounds represented in general formula (1) and a salt thereof are useful for glucocorticoid receptor modulator.
The R 1 represents a hydrogen atom or a lower alkyl group; R 2 represents...
|
|
|
US20090298742 |
PROCESS FOR MANUFACTURING LACTOSE
A process for forming crystalline lactose suitable for use in a pharmaceutical formulation comprises subjecting a solution comprising a plurality of nanosized lactose particles to conditions...
|
|
|
US20090291980 |
TRIGLYCERIDE-LOWERING AGENT AND HYPERINSULINISM-AMELIORATING AGENT
The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent. The triglyceride-lowering agent and...
|
|
|
US20090291948 |
SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE
Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the...
|
|
|
US20090291904 |
CHEMICAL DERIVATIVES OF JASMONATE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
The present invention relates to novel jasmonate derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and...
|
|
|
US20090286828 |
2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES
The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in...
|
|
|
US20090286776 |
HEXENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC APPLICATIONS THEREOF
Compounds of the formula (I): in which R, R 1 , R 2 and R 3 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical...
|
|
|
US20090281103 |
Renin Inhibitors
The present invention relates to novel renin inhibitors of the general Formula (I), and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also...
|
|
|
US20090280982 |
Quinolinylmethyl Compounds
The present invention relates to novel biphenyl-4-sulfonicacid (quinolin-4-ylmethyl)-amide compounds of formula (I) wherein R 1 and R 2 are halogen, OH, CN, NH 2 , NO 2 , C 1 -C 6 -alkyl, C 2 -C...
|
|
|
US20090275611 |
Compounds Which Modulate The CB2 Receptor
Compounds are provided which bind to and are agonist, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula (I) wherein R 1 , R 2 , R 3 , X and Ar have the...
|
|
|
US20090275608 |
Methods of diagnosing and treating parp-mediated diseases
Disclosed are methods of identifying a disease treatable with modulators of differentially expressed genes in a disease, including at least PARP modulators, by identifying the level of expression...
|
|
|
US20090275524 |
NOVEL HYPOCHOLESTEROLEMIC COMPOUNDS
The present invention relates to novel hypocholesterolemic compounds of formula (I) useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as...
|
|
|
US20090270408 |
AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF
The invention relates to novel amide derivatives that are PAMs of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such...
|
|
|
US20090264463 |
Inhibitors Of Protein Phosphatase-1 And Uses Thereof
Inhibitors of Protein Phosphatase-1 have been shown to slow replication of HIV-1. Inhibitors of PP 1 and their use for treatment or prevention of HIV-1 infections are disclosed.
|
|
|
US20090263453 |
Methods and Compositions for Treating Pain Comprising a Statin
Methods and compositions are provided for reducing, treating or preventing pain and/or inflammation in a patient in need of such treatment, the methods and compositions comprising administering a...
|
|
|
US20090258070 |
Topical LFA-1 antagonists for use in localized treatment of immune related disorders
This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for topical delivery. In particular, the LFA-1 antagonists are...
|
|
|
US20090253740 |
SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS
This invention provides a compound of the formula (I): And their use for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This...
|
|
|
US20090253656 |
BCRP/ABCG2 INHIBITOR
The present invention is directed to a breast cancer resistance protein (BCRP/ABCG2) inhibitor. The BCRP inhibitor contains, as an active ingredient, an acrylonitrile derivative represented by...
|
|
|
US20090247575 |
STABILIZING LIPID COMPOSITIONS FOR ORAL PHARMACEUTICAL AGENTS
The present invention relates to a pharmaceutical composition for oral administration comprising an exceptionally labile active agent, a stabilizing vehicle comprising liquid triglycerides and a...
|
|
|
US20090239906 |
ALKOXYALKYL-SUBSTITUTED CYCLIC KETOENOLS
The invention relates to new alkoxyalkyl-substituted cyclic ketoenols of the formula (I)
in which
A, B, D, G, W, X and Y have the definitions indicated above,
to processes and intermediates...
|
|
|
US20090239841 |
Diaryl Ureas as CB1 Antagonists
Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the...
|
|
|
US20090233963 |
METHODS TO DETERMINE SUCEPTIBILITY TO TREATMENT WITH LEUKOTRIENE MODIFIERS
The present invention provides a method of determining the susceptibility of a subject to treatment with a leukotriene modifier by determining the subject's cysteinyl leukotriene (CysLT) level and...
|
|
|
US20090233962 |
Amide derivative and insecticide containing the same
The present invention is to provide a compound represented by the general formula (1) exhibiting a high insecticidal effect and an insecticide comprising the compound as an active ingredient. The...
|
|
|
US20090227582 |
Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of...
|
|
|
US20090221535 |
IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
The present invention is directed to compounds of Formula I: I (where A 1 , A 2 , B 1 , B 2 , B 3 , B 4 , D 1 , D 2 , T, U, V, W, X, Y, Z. R 4 , R 5a ?, R 5b , R 5c , R 6 , m and n are defined...
|
|
|
US20090220583 |
Method and composition for treating inflammatory disorders
There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome...
|
|
|
US20090215819 |
ANTI-INFECTIVE AND IMMUNOMODULATORY COMPOUNDS
The present invention provides pharmaceutical compositions and methods that include the use of anti-infective compounds that potentiate the host-immune response or limit or prevent the expression...
|
|
|
US20090215773 |
DIHYDROPYRIDINE DERIVATIVES
The present invention relates to dihydropyridine derivatives having general formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 is (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl,...
|
|
|
US20090209564 |
Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use
Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also...
|
|
|
US20090197858 |
HYPERCHOLESTROLEMIA AND TENDINOUS INJURIES
This invention provides compositions and methods of inhibiting, suppressing, or treating a tendinous or musculoskeletal soft tissue injury. The invention further provides a method of ameliorating...
|
|
|
US20090192190 |
Benzoic Acid Derivatives that are Modulators or Agonists of GlyR
Compounds of formula I,
wherein R1, Z, Y, M and R2 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical composition containing the same, methods of...
|
|
|
US20090191183 |
SUBSTITUTED INDOLES
Disclosed herein are substituted indole cysteinyl leukotriene receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
|
|
|
US20090182010 |
COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
This invention provides compounds of formula I:
wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8a , R 8b , W, a and bare as defined in the specification, or a pharmaceutically...
|
|
|
US20090182008 |
CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM
The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form....
|
|
|
US20090181111 |
Saponin And Preservative Compositions For Reduction of Protozoa
The invention is related to methods and compositions for reducing protozoa populations in animals. In an embodiment, the invention includes a method for reducing protozoal populations including...
|
|
|
US20090176745 |
TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS
Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions...
|
|
|
US20090170840 |
NS1 protein inhibitors
The present invention generally relates to compounds to treat viral infections and methods of their use. In particular, compounds of the present invention inhibit the activity of NS1 protein,...
|
|
|
US20090169583 |
Solid Adsorbates of Hydrophobic Drugs
A solid pharmaceutical composition comprises a solid adsorbate comprising a hydrophobic drug, a lipophilic vehicle, and a porous substrate, wherein the hydrophobic drug and lipophilic vehicle are...
|
|
|
US20090163543 |
Histone Deacetylase Inhibitors and Methods of Use Thereof
One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for...
|
|
|
US20090163523 |
Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
The invention provides a pharmaceutical combination comprising: a) at least one S1P receptor agonist, and b) at least one JAK3 kinase inhibitor and a method for treating or preventing autoimmune...
|
|
|
US20090162442 |
MULTI-PHASIC, NANO-STRUCTURED COMPOSITIONS CONTAINING A COMBINATION OF A FIBRATE AND A STATIN
The present invention discloses a pharmaceutical formulation containing a multi-phasic pharmaceutical composition in an oral dosage form. The multi-phasic pharmaceutical composition contains: (a) a...
|
|
|
US20090162439 |
SILK FIBROIN COATING
The present invention is directed to compositions and methods for preventing or inhibiting biofilm formation on a solid substrate comprising an antimicrobial agent and a biofilm-degrading enzyme...
|
|
|
US20090155180 |
Methods and targets for identifying compounds for regulating rhinovirus infection
The present invention provides methods for identifying genes, expression regulators, receptors, protein product receptors, and proteins that may regulate rhinovirus infections. The genes identified...
|
|
|
US20090149496 |
INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL
The invention relates to the use of Kv1.5 inhibitors for the therapy or prophylaxis of respiratory disorders, sleep-related respiratory disorders, central and obstructive sleep apneas, upper airway...
|
|
|
US20090148384 |
FUNCTIONALIZED, SOLID POLYMER NANOPARTICLES COMPRISING EPOTHILONES
The present invention describes polymer nanoparticles with a cationic surface potential, in which both hydrophobic and hydrophilic pharmaceutically active substances can be encapsulated. The...
|
|
|
US20090143425 |
COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY
This invention relates to novel quinoline compounds which affect gap junction activity. Also provided are methods of using such compounds and compositions containing the compounds to treat gap...
|